

1. Andeen NK, Smith KD, Vasilescu E-R, Batal I. Fibrillary glomerulonephritis is associated with HLA-DR7 and HLA-B35 antigens. *Kidney Int Rep.* 2020;5:1325–1327.
2. El Ters M, Bobart SA, Cornell LD, et al. Recurrence of DNAJB9-positive fibrillary glomerulonephritis after kidney transplantation: a case series. *Am J Kidney Dis.* 2020;76:500–510.
3. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. *Hum Immunol.* 2007;68:779–788.

Mireille El Ters<sup>1,2</sup>, Manish J. Gandhi<sup>3</sup>, Ann M. Moyer<sup>4</sup>, Samih H. Nasr<sup>4</sup> and Mariam P. Alexander<sup>4</sup>

<sup>1</sup>Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; <sup>2</sup>William von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA; <sup>3</sup>Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA; and <sup>4</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

**Correspondence:** Mireille El Ters, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA. E-mail: [elters.mireille@mayo.edu](mailto:elters.mireille@mayo.edu)

Received 24 July 2020; accepted 11 August 2020; published online 22 August 2020

*Kidney Int Rep* (2020) 5, 1841; <https://doi.org/10.1016/j.ekir.2020.08.015>

© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**The Authors Reply:** We reported a significant positive association of each of human leukocyte antigen (HLA)-DR7 and HLA-B35 with fibrillary glomerulonephritis (FGN) in a cohort of 26 patients with FGN.<sup>1</sup> We are pleased that El Ters *et al.*<sup>2</sup> have observed a similar association between HLA-DR7 and FGN in their cohort of 16 patients with native kidney failure due to FGN or donor-derived FGN. Together, these findings support a genetic component to this rare glomerulonephritis.

Unlike our study, HLA-B35 was not significantly associated with FGN in the Mayo Clinic cohort,<sup>2</sup> raising uncertainty about the significance of HLA-B35 association with FGN. HLA antigens have associations with race and infectious and autoimmune diseases, that may confound analyses of small cohorts. HLA-B35 is one of the largest allelic Class I molecules.<sup>3</sup> HLA-B35 appears to increase susceptibility to chronic hepatitis C virus

infection in particular populations,<sup>4</sup> and hepatitis C infection is significantly associated with Black patients in the setting of FGN.<sup>S1,S2</sup> In small cohorts, differences in ethnicity and concurrent diseases may affect the ability to confirm genetic associations.

Larger, ethnicity-matched cohorts are needed to confirm the associations that have been described between HLAs and FGN. Importantly, future investigations may benefit from molecular typing for both HLA Class I and Class II, and from applying genome-wide association studies to more specifically decipher genetic susceptibility loci in patients with FGN beyond serologic typing of HLA antigens.

## SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Supplementary References.

1. Andeen NK, Smith KD, Vasilescu E-R, Batal I. Fibrillary glomerulonephritis is associated with HLA-DR7 and HLA-B35 antigens. *Kidney Int Rep.* 2020;5:1325–1327.
2. El Ters M, Gandhi MJ, Moyer AM, et al. Letter regarding “fibrillary glomerulonephritis is associated with HLA-DR7 and HLA-B35 antigens.” *Kidney Int Rep.* 2020;5:1840–1841.
3. Cereb N, Kim C, Hughes AL, Yang SY. Molecular analysis of HLA-B35 alleles and their relationship to HLA-B15 alleles. *Tissue Antigens.* 1997;49:389–396.
4. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. *World J Gastroenterol.* 2007;13:1770–1787.

Nicole K. Andeen<sup>1</sup>, Kelly D. Smith<sup>2</sup>, Elena-Rodica Vasilescu<sup>3</sup> and Ibrahim Batal<sup>3</sup>

<sup>1</sup>Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA; <sup>2</sup>Department of Pathology, University of Washington, Seattle, Washington, USA; and <sup>3</sup>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA

**Correspondence:** Nicole Andeen, Department of Pathology, Oregon Health & Science University, Portland, Oregon 97239-3098, USA. E-mail: [andeen@ohsu.edu](mailto:andeen@ohsu.edu)

Received 10 August 2020; accepted 12 August 2020; published online 20 August 2020

*Kidney Int Rep* (2020) 5, 1841; <https://doi.org/10.1016/j.ekir.2020.08.014>

© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).